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ABSTRACT
Objectives To update cost effectiveness estimates for the
four dose (3+1) schedule of the seven valent
pneumococcal conjugated vaccine (PCV-7) in the
Netherlands and to explore the impact on cost
effectiveness of reduced dose schedules and
implementation of 10 valent and 13 valent pneumococcal
vaccines (PCV-10 and PCV-13).
Design Economic evaluation comparing PCV-7, PCV-10,
and PCV-13 with no vaccination using a decision tree
analytic model built from data in previous studies.
Setting The Netherlands.
Population A cohort of 180000 newborns followed until
5 years of age.
Main outcome measures Costs; gains in life years and
quality adjusted life years (QALYs); and incremental cost
effectiveness ratios.
ResultsUnder base case assumptions—that is, assuming
a five year protective period of the vaccine and no
assumed net indirect effects (herd protection minus
serotype replacement) among children aged over 5 years
—vaccination with PVC-7 in a four dose (3+1) schedule
was estimated to prevent 71 and 5778 cases of invasive
and non-invasive pneumococcal disease, respectively, in
children aged up to 5 years. This corresponds with a total
net gain of 173 life years or 277 QALYs. The incremental
cost effectiveness ratio of PCV-7 was estimated at
€113891 (£98300; $145000) per QALY, well over the
ratio of €50000 per QALY required for PCV-7 to be
regarded as potentially cost effective. A three dose (2+1)
schedule of PCV-7 reduced the incremental cost
effectiveness ratio to €82975 per QALY. For various
assumptions and including 10% of the maximum net
indirect effects among individuals aged 5 years and over,
PCV-10 and PCV-13 had incremental cost effectiveness
ratios ranging from €31250 to €52947 per QALY.
Conclusions The current Dutch infant vaccination
programme of four doses of PCV-7 is not cost effective
because of increases in invasive disease caused by non-
vaccine serotypes, which reduces the overall direct
effects of vaccination and offsets potential positive herd
protection benefits in unvaccinated individuals. The 10
valent and 13 valent pneumococcal vaccines could have
better net health benefits than PCV-7 through less
replacement disease and increased herd protection. Both
these effects could substantially reduce the incremental
cost effectiveness ratio to possibly acceptable levels, if
total programme costs can be lowered by reduced
schedules, reductions in vaccine prices, or both.
INTRODUCTION
Given the multitude of new vaccines available for
introduction into national immunisation programmes,
health economic modelling of various immunisation
plans is becoming increasingly important in informing
decisions on health policy. The decision to introduce
the seven valent pneumococcal conjugated vaccine
(PCV-7) into the Dutch national immunisation pro-
gramme for infants, for example, has in part been dri-
ven by cost effectiveness considerations.1 The Dutch
Health Council estimated the incremental cost effec-
tiveness ratio of vaccination with PCV-7 compared
with no vaccination at €70 000 (£60 300; $89 200) and
less than €20 000 per quality adjusted life year (QALY)
in 2001 and 2005, respectively.1 Crucial factors
responsible for the change fromapotentially unfavour-
able cost effectiveness ratio in 2001, exceeding €50 000
perQALY, to a favourable ratio in 2005were the inclu-
sion of data on observed herd protection effects in
adults after nationwide implementation of PCV-7 in
the USA in 2000 and limited disease development
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PCV-7 replacing pneumococcal serotypes eliminated
by the vaccine (replacement disease).2-4
Next to direct effects on invasive disease in vacci-
nees, expected savings from herd protection were
also part of health economic studies in other European
countries that introduced PCV-7 into their national
immunisation programmes.5-10 Both the four dose
(3+1) vaccine schedule and the reduced three dose
(2+1) schedule, as implemented in Norway and
the UK,11 12 are highly effective against invasive
pneumococcal disease caused by vaccine serotypes.
However, the net overall benefit of national immu-
nisation programmes in many European countries
has been reduced by increases in invasive disease
caused by non-vaccine serotypes.12-15 Importantly, in
the first 18-30 months after the introduction of PCV-
7 in the Netherlands, France, and the UK, no overall
reduction in invasive disease in non-vaccinees was
observed.12 13 15
Given that both increases in invasive disease caused
by non-vaccine serotypes and absence of herd protec-
tion may considerably affect the cost effectiveness of
the current Dutch vaccination programme, we set out
to update cost effectiveness estimates for the current
four dose schedule of PCV-7 by using recent data on
epidemiology and resource use. Also, we investigate
the cost effectiveness of reduced dose schedules and
vaccine price reductions combined with the
implementation of 10 valent and 13 valent pneumo-
coccal vaccines (PCV-10 and PCV-13).
METHODS
Model
We designed a decision tree analytic model structure
that builds on our previously reported model.6 16 Var-
ious data sources were used to populate our model;
these included clinical trials and observational studies
for effectiveness of pneumococcal vaccines, laboratory
data for incidence and serotype distributions of pneu-
mococcal disease, and registrations for resource useand
costs. Figure 1 shows the disease model for the health
effects of pneumococcal vaccination, including the pos-
sibility of subsequent pneumococcal disease such as
non-invasive pneumonia, otitis media, and invasive
pneumococcal disease. Assumptions regarding both
costs and quality of life are summarised in table 1 and
are more thoroughly discussed in web extra 1.
In the analyses, a cohort of 180000 newborns, repre-
senting the Dutch birth cohort, was run through the
decision tree twice (base case analysis): once as amainly
vaccinated cohort (PCV-7/PCV-10/PCV-13); andonce
as an unvaccinated cohort. The analytic time frame of
the study was five years because vaccine effectiveness
could not be assumed beyond five years. However,
long term effects of invasive pneumococcal disease
were extrapolated over the full lifetime of the indivi-
duals in the cohort (that is, until death or 100 years).
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Fig 1 | Decision tree used in conjunction with the cohort of 180000 newborns. Numbers between brackets correspond to data shown in table 1. The boxes
represent decision nodes, with green colour indicating probabilistic states and red colour indicating end states. The “No vaccination” arm is a clone of the
“Vaccination of all healthy infants” arm (as represented by the + sign; risks differ between both arms)
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Table 1 | Parameters used in the economic model
Mean or range Distribution
Corresponding
branches in fig1 References
Case-fatality rate (birth cohort)
Meningitis 9% Beta (3,32) 5 17
Pneumonia 0% N/A N/A 17
Bacteraemia with focus 0% N/A N/A 17
Bacteraemia without focus 9% Beta (2,21) 6 17
Mortality (non-invasive pneumonia and acute otitis media) 0% N/A N/A Assumed
Case-fatality rate (age five years or older)
Meningitis 9-92% Beta (age dependent) 5 17
Pneumonia 0-29% Beta (age dependent) 7 17
Bacteraemia with focus 0-33% Beta (age dependent) 8 17
Bacteraemia without focus 9-67% Beta (age dependent) 6 17
Respiratory infections 0% N/A N/A Assumed
Vaccine efficacy
Invasive pneumococcal disease (all vaccine serotypes) 97.4% Log normal (SE 0.044) 1 19
Non-invasive pneumonia (admitted to hospital) 11.1% Log normal (SE 0.082) 2 23
Non-invasive pneumonia (seen by general practitioner) 6.0% Log normal (SE 0.032) 3 23
Acute otitis media 7.0% Log normal (SE 0.011) 4 22
Direct costs (€)
Cost of hospital admission*
Invasive pneumococcal disease (age dependent) 1091-27 318 Triangular (age dependent) 1 17, 39
Non-invasive pneumonia 26-2614 Triangular (severity dependent) 9 16, 39, 40
Acute otitis media 17-381 Triangular (severity dependent) 4 16, 39, 40
Special education (annual costs) 9 798-16 962 Triangular (age dependent) 10 16
Institutional care (annual costs) 39 583 Triangular (29,687; 39,583; 49,478) 11 39
Cochlear implantation 56 633 Triangular (0; 0.004; 0.01) 12 41
Indirect costs (€)
Invasive pneumococcal disease† 0-974 Triangular (severity dependent) 1 17, 39
Non-invasive pneumonia (admitted to hospital)‡ 0-2529 Triangular (severity dependent) 1 17, 39
Non-invasive pneumonia (seen by general practitioner)† 115-315 Triangular (severity dependent) 9 16, 39
Acute otitis media† 58-23 Triangular (severity dependent) 4 16, 39
Total drop in quality of life (QALYs)
Disability§ 0.53 Beta (estimated) 11 42
Bilateral hearing loss (first year)§ 0.45 Beta (estimated) 12 8, 43
Bilateral hearing loss: cochlear device§ 0.18 Beta (estimated) 12 8, 43
All other hearing loss§ 0.09 Beta (estimated) 13 42
Hospital admission for bacteraemia** 0.0079 Beta (estimated) 14 8, 44
Hospital admission for meningitis 0.0232 Beta (estimated) 15 8, 44
Hospital admission for non-invasive pneumonia¶ 0.006 Triangular (0.001, 0.006, 0.01) 2 8
Non-invasive pneumonia treated by a general practitioner¶ 0.004 Triangular (0, 0.004, 0.01) 3 8
Acute otitis media¶ 0.005 Triangular (0, 0.005, 0.01) 4 8
Other parameters
Increase in non-vaccine serotype of invasive pneumococcal disease †† 100% Triangular (50%, 100%, 150%) N/A 12, 13††
Net indirect effect for PCV-10 and PCV-13‡‡ 10% Triangular (0%, 10%, 30%) N/A Assumed‡‡
Discount rate health effects 1.5% N/A N/A 27
Discount rate costs 4% N/A N/A 27
*Based on the average duration of hospital stay (both intensive care and general ward) and corresponding unit costs.39 See also web table B for age specific costs of hospital admission.
†Indirect costs caused by absence at work of parents taking care of their children.
‡Indirect costs caused by absence at work of patient due to hospital admission.
§Per year.
¶Per case.
**Same QALY decrement was assumed for invasive pneumonia, bacteraemia with focus, and bacteraemia without focus.
††See also web extra 2. Indirect effects in the analysed birth cohort.
‡‡See also web extra 3. Indirect effects for those aged 5 years and older.
PCV-7/10/13, seven/10/13 valent pneumococcal conjugated vaccine.
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Baseline disease risks
Surveillance data on the incidence and serotype distri-
bution of invasive pneumococcal disease before
national implementation of PCV-7 were available for
the period 2004-2006, including data on age, primary
focus of infection, resource use, hospital admission,
and outcome.13 17 The case-fatality rate for meningitis
and bacteraemia without focus in children was esti-
mated to be 9% (table 1), 17 which is in line with the
international literature. 5 8 18 Invasive pneumonia and
bacteraemia with focus were assumed not to result in
death in children.17 In our model, severe mental and
physical handicap resulting from meningitis was
assumed to occur in 13% of cases of pneumococcal
meningitis in children, of which 50% would require
special education and 25% intensive “round the
clock” institutional care. 6 Jansen et al found that hear-
ing problems occurred in 32%of cases ofmeningitis, of
which 50% were serious enough to require a cochlear
hearing device. 17 Baseline risks for non-invasive pneu-
monia requiring hospital admission and for non-inva-
sive pneumonia and acute otitis media treated in
general practitioner surgeries were estimated from
national hospital and general practitioner records,
respectively (see web table A).
Vaccine efficacies
Vaccine efficacy against invasive pneumococcal disease
was assumed at 97.4% after two doses for all seven ser-
otypes of pneumococcal disease covered by PCV-7
(table 1).19 This value seems to be a conservative esti-
mate if one takes into account the fact that only one vac-
cine failure has been reported in the Netherlands in the
first two years after introduction of routine infant vacci-
nation in June 2006. Routine vaccination for infants in a
2+1 dose schedule was introduced in Norway in 2006,
and similarlynovaccine failureshadoccurredup to June
2008.11 Protection against invasive disease was thus esti-
mated to last for five years in the base case analysis.20
Furthermore, in randomised controlled settings, the vac-
cine was shown to be effective against non-invasive
pneumonia and otitis media in children.21-23 For non-
invasive pneumonia, efficacy of pneumococcal vaccina-
tion seems to increase with diagnostic certainty.23
In our model, we applied the efficacy estimate of
11.1% for “clinical pneumonia and perihilar findings”
to children admitted to hospital with the diagnosis of
pneumonia in the Netherlands.23 This definition of
pneumonia seems to best fit the types of pneumonias
treated in Dutch hospitals. An efficacy of 6.0% was
assumed for patients who visited a general practitioner
and were diagnosed with pneumonia.23 In two rando-
mised studies, PCV-7 was found to prevent 6.4% to
7.0% of all cases of acute otitis media.22 19 24 The inter-
pretation of these studies for the Dutch setting is ham-
pered by several factors, including the fact that the
causal micro-organism is not recorded in cases of otitis
media in the Netherlands. In our model, we used an
overall efficacy estimate of 7.0% for otitis media on
the basis of the most recent data from the Kaiser Per-
manente trial.22Given evidence for the durationof pro-
tection against non-invasive pneumonia and recentUS
surveillance data, we assumed that vaccinated children
were protected against non-invasive pneumonia and
otitis media up to their second year of life, starting
after the second dose of the vaccine.21 25 26
A vaccine efficacy of 97.4% against all serotypes
included was assumed for PCV-10 and PCV-13, simi-
lar to the assumed efficacy of PCV-7. In the absence of
clinical data on the efficacy of PCV-10 and PCV-13
against non-invasive pneumonia and acute otitis
media, the efficacy of these two vaccines was assumed
to increase proportionallywith the increase in serotype
coverage for invasive pneumococcal disease.
Indirect effects
As well as estimations of the direct effects, we also esti-
mated indirect effects of vaccination in our model. We
included in our base case analysis herd protection
against invasive pneumococcal disease for children in
the birth cohort not yet fully protected by the vaccine
and for non-vaccinated children, assuming this protec-
tion would be as effective as vaccination (table 2). 12 13
We also increased the incidence of invasive pneumo-
coccal disease caused by non-vaccine serotypes to
Table 2 | Base case serotype coverage and efficacy for direct effects and assumptions on indirect effects for the analysed birth cohort and the remaining
population (those aged 5 years or older) for PCV-7, PCV-10, and PCV-13
PCV-7 PCV-10 PCV-13
Serotypes covered 4, 6B, 9V, 14,
18C, 19F, 23F
4, 6B, 9V, 14, 18C,
19F, 23F, 1, 5, 7F
4, 6B, 9V, 14, 18C,
19F, 23F, 3, 6A, 19A,1,5,7F
Increase in invasive pneumococcal disease caused by non-vaccine serotypes in the analysed
birth cohort (serotype replacement)
100% 100% 100%
Efficacy and level of herd protection against vaccine serotypes of invasive pneumococcal disease
in the analysed birth cohort*
97.4% 97.4% 97.4%
Net indirect effect in the remaining population† 0% 10% 10%
*Herd protection was assumed for the entire birth cohort, including those not yet (fully) protected by the vaccine (either infants too young to be vaccinated or those who received only a
single dose of the vaccine) and non-vaccinated children (5% of a birth cohort for the Netherlands), assuming a protection effect of 97.4% against vaccine serotypes, similar to the efficacy of
the vaccine.
†Net indirect benefits are defined as the benefits resulting from protection against invasive pneumococcal disease caused by vaccine serotypes minus the increase of invasive pneumococcal
disease caused by non-vaccine serotypes. The potential maximum was defined as full reduction in invasive pneumococcal disease cases caused by vaccine serotypes in the absence of any
replacement disease. Lower percentages can be defined as a combination of a decrease in vaccine serotype invasive pneumococcal disease and an increase in disease from in non-vaccine
serotypes.
PCV-7/10/13, seven/10/13 valent pneumococcal conjugated vaccine.
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100% for the analysed birth cohort (that is, we doubled
the incidenceof invasive pneumococcal disease caused
by non-vaccine serotypes) on the basis of surveillance
data from early after national introduction of PCV-7 in
the Netherlands and the UK.12 13 See web extra 2 for a
more in depth description of the assumptions for our
estimation of indirect effects in the birth cohort.
No serotype information for acute otitis media and
non-invasive pneumonia is available in the Nether-
lands, and serotype replacement for these diseases
may be assumed to be already included in the vaccine
efficacy estimates in the first efficacy studies.21-23 There-
fore, we did not include an additional increase of non-
vaccine serotype disease but also left out potential herd
effects for otitis media and non-invasive pneumonia
(see web extra 2).
We assumed in our base case analysis for PCV-7 that
no net indirect effect would exist for individuals out-
side the modelled cohort. This assumption was made
because no reduction in the incidence of invasive
pneumococcal disease has been observed after the
introduction of routine vaccination with PCV-7 for
individuals 5 years of age or older and because the
observed herd protection effect in the UK in the third
year after introducing routine vaccination was
completely counteredby a rise in invasive pneumococ-
cal disease caused by non-vaccine serotypes.12 In this
respect, net indirect effects are defined as cases of inva-
sive disease averted by herd protectionminus invasive
cases of replacement disease.
Net indirect effects may occur in the future, espe-
cially if serotype coverage is extended by a change
from seven serotype vaccines to vaccines with broader
serotype coverage.1317 Therefore, in the base case ana-
lysis for PCV-10 and PCV-13, a net indirect effect for
invasive disease at 10% of the potential maximum was
applied for those aged5years or older (seewebextra 3).
In particular, the potential maximum was defined as
prevention of all cases of invasive disease caused by
serotypes in the vaccine and absence of any replace-
ment disease. Net protective indirect benefits against
otitis media and non-invasive pneumonia were not
included in any of the analyses.25
Given that there ismuchuncertainty about thedevel-
opment of indirect effects, these assumptions were var-
ied over a wide range in the sensitivity analyses.
Outcome measures and cost effectiveness analysis
The simulation model tracks all the specific disease
cases and the deaths, costs, changes in QALYs and
life years, and indirect effects (herd protection and ser-
otype replacement).Wewere able to determine the net
costs andnet life years andQALYsgainedby summing
all the costs, life years, and QALYs and calculating the
differences for the evaluations with and without vacci-
nation. The incremental cost effectiveness ratio was
calculated by dividing the net costs by either life
years or QALYs. Health effects and cost were dis-
counted at 1.5% and 4% for time preference, respec-
tively, according to the Dutch guidelines for cost
effectiveness research.27
Incremental cost effectiveness ratios for routine vac-
cination were calculated by comparing different vacci-
nation schedules against no vaccination. Following
recently published evidence on the efficacy of PCV-7
in reduced dose schedules,28 29 we investigated the
effect of a three dose schedule (that is, 2+1) to test the
effect of lower total vaccination costs (see web extra 4).
We also forecasted the incremental cost effectiveness
of potential shifts from PCV-7 to pneumococcal vac-
cines that include additional serotypes (that is, PCV-10
and PCV-13).
For PCV-7, the estimated current cost of €50 per
dose within the Dutch national immunisation pro-
gramme was used.6 16 For PCV-13, the officially listed
price of €68.56 was applied, with administration costs
of €5.95 being added (total cost per dose €74.51).16 For
PCV-10, no officially listed price is available in the
Netherlands. Given that we know the pricing of
PCV-10 in other countries is conservative compared
with PCV-13, we assumed the total cost per dose of
PCV-10 at the midpoint between PCV-7 and PCV-13
(that is, €62.25).30









disease related to net indirect
effects for individuals aged
5 years or older* Total
Cases (undiscounted)
No vaccination 170 788 19 385 188 2410 NA
PCV-7 165 416 18 979 117 210 NA
PCV-10 164 664 18 922 80 2260 NA
PCV-13 163 912 18 865 38 2229 NA
Cases averted
PCV-7 5372 406 71 0 NA
PCV-10 6124 463 108 150 NA
PCV-13 6876 520 150 181 NA
QALYs gained (years)
PCV-7 27 2 248 0 277
PCV-10 30 2 361 314 707
PCV-13 34 2 470 384 891
Life years gained (years)
PCV-7 0 0 173 0 173
PCV-10 0 0 255 312 566
PCV-13 0 0 336 381 717
Direct savings (€1000s), excluding vaccination costs
PCV-7 126 375 1725 0 2226
PCV-10 144 427 2454 1398 4422
PCV-13 161 479 3181 1696 5518
Indirect savings (€1000s; direct effects) related to production losses
PCV-7 320 74 46 0 440
PCV-10 365 84 67 161 677
PCV-13 410 94 93 202 799
*Only net indirect effects against invasive pneumococcal disease were included in the model for individuals
aged 5 years or older. For PCV-7, no net indirect effects were included into the model for individuals aged
5 years or older in the base case analysis.
NA, not applicable; PCV-7/10/13, seven/10/13 valent pneumococcal conjugated vaccine; QALY, quality
adjusted life years.
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Scenario and sensitivity analyses
We performed univariate, threshold, scenario, and
probabilistic sensitivity analyses. In the univariate sen-
sitivity analyses, all relevant parameterswere variedby
25% to explore the impact of eachparameter relative to
each other. One specific threshold analysis was per-
formed in which the effect of the parameter on the
incremental cost effectiveness ratio was investigated
by varying the net indirect effects on individuals aged
5 years or older over a range of 0% to 30%. For the
probabilistic sensitivity analyses, parameterswere gen-
erated using Monte Carlo sampling, with outcome
values generated by running the model 5000 times.
Log normal, beta, and triangular distributions were
used except for multinomial probabilities, where
Dirichlet distributions were assumed (see table 1 for
specific distributions).
RESULTS
Cost effectiveness of PCV-7
In the base case analysis, the estimated burden of pneu-
mococcal infection for a birth cohort followed for five
years was 170 788 cases of acute otitis media and
19 385 cases of non-invasive pneumonia, of which
2645 cases would result in hospital admission (table 3).
Applying the base case assumptions, 5372 (31%) cases
of acute otitis media and 406 (21%) cases of non-
invasive pneumonia would be prevented by vaccina-
tion with PCV-7, corresponding to gains of 27 and 2
QALYs, respectively.
Additionally, 188 cases of invasive pneumococcal
disease a year were estimated in children under
5 years of age: 65 cases of meningitis; 45 cases of inva-
sive pneumococcal disease; 38 cases of bacteraemia
with focus; and 40 cases of bacteraemia without
focus. In total, 71 (38%) cases of invasive disease
would be prevented by vaccinationwith PCV-7, corre-
sponding to a total gain of 173 life years or 248QALYs.
In addition to the health gains, vaccination with
PCV-7 would also prevent approximately €2.2million
of direct costs and €0.4 million of indirect costs.
Assuming a four dose schedule, the annual cost of vac-
cination is estimated at €34.2 million. Dividing the
incremental costs by the incremental health benefits
results in an incremental cost effectiveness ratio of
€113 891 per QALY gained for PCV-7. An incremen-
tal cost effectiveness ratio of less than €50 000 per
QALY would be required for PCV-7 to be regarded
as potentially cost effective. Shifting from a 3+1 dose
schedule to a 2+1 regimen could improve cost effec-
tiveness of PCV-7 to €82 975 per QALY (table 4).
Cost effectiveness of PCV-10 and PCV-13
Compared with no vaccination, vaccination with
PCV-10 would prevent 6124 cases of otitis media,
463 cases of non-invasive pneumonia, and 258 cases
of invasive pneumococcal disease, of which 150
would be averted by net indirect effects in individuals
aged 5 years and older. Overall these health benefits
would result in a gain of 707QALYs.Vaccinationwith
PCV-13 would prevent 6876 cases of otitis media, 520
cases of non-invasive pneumonia, and 331 cases of
invasive pneumococcal disease, resulting in a total
gain of 891 QALYs.
Dividing the incremental costs by the incremental
health benefits for the 10 valent and 13 valent vaccines
produced incremental cost effectiveness ratios of
€52 947 and €50 042 per QALY for PCV-10 and
PCV-13, respectively. A 2+1 dose schedule could
reduce these incremental cost effectiveness ratios to
€37 891 for PCV-10 and to €35 743 for PCV-13
(table 4). A 25% reduction in the vaccine price of
PCV-10 and PCV-13 (to €50 per dose, the cost of
Table 4 | Incremental cost effectiveness ratios in the base case analysis, sensitivity analysis, and several scenario analyses
PCV-7 (€/QALY) PCV-10 (€/QALY) PCV-13 (€/QALY)
3+1 dose schedule
Without net positive indirect effects for individuals aged 5 years or older* 113 891† 99 151 91 705
With 10% net positive indirect effects for individuals aged 5 years or older* 59 937 52 947† 50 042†
With 20% net positive indirect effects for individuals aged 5 years or older* 39 698 35 146 33 479
2+1 dose schedule
Without net positive indirect effects for individuals aged 5 years or older* 82 975 72 083 66 572
With 10% net positive indirect effects for individuals aged 5 years or older* 43 070 37 891 35 743
With 20% net positive indirect effects for individuals aged 5 years or older* 28 101 24 718 23 488
Reduction in the cost of the vaccine (€50 per dose)‡ NA† 41 106 31 250
Excluding herd effects in the analysed birth cohort for invasive pneumococcal disease‡ 129 069 57 770 55 055
Including herd effects in the analysed birth cohort for non-invasive pneumococcal disease‡ 111 153 52 211 49 407
Higher utility losses‡ § 67 581 40 136 38 664
Exclusion of productivity losses (analysis from a healthcare perspective)‡ 115 481 53 904 50 938
Efficacy against acute otitis media‡ ¶ 78 527 43 048 41 457
*Inclusion of net positive indirect effects (herd protection against vaccine serotype disease minus increases in non-vaccine serotype pneumococcal disease). See also web extra 2.
†Base case scenario.
‡Scenarios were calculated holding all other assumptions, similar to the base case analysis (that is, with no net indirect benefits for PCV-7 and 10% net indirect benefits for PCV-10 and
PCV-13).
§Utilities reported by Prosser et al were used for children aged up to 5 years old.40
¶Efficacy against acute otitis media was assumed to be 33.6%, as was shown for the precursor vaccine of PCV-10 by Prymula et al.41
NA, not applicable; PCV-7/10/13, seven/10/13 valent pneumococcal conjugated vaccine; QALY, quality adjusted life year.
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PCV-7) would reduce the cost effectiveness ratios to
€41 106 and €31 250, respectively. Assuming both a
dose (to three doses) and a price reduction (to €50 per
dose), the cost effectiveness ratios for PCV-10 and
PCV-13 would be as low as €29 013 and €21 654 per
QALY, respectively
Scenario and sensitivity analyses
Figure 2 shows the parameters that produced the lar-
gest variation in the cost effectiveness ratio for PCV-7
when varied by 25%. Apart from vaccine efficacy
against invasive pneumococcal disease, the most
important determinants of the cost effectiveness of
PCV were the total vaccination costs, the increase in
invasive pneumococcal disease caused by non-vaccine
serotypes, and the case fatality rate for meningitis. In
univariate sensitivity analyses for PCV-10 and PCV-
13, generally similar but smaller changes in the incre-
mental cost effectiveness ratio were observed. The
changes were smaller because of the relative impor-
tance of indirect benefits in the unvaccinated popula-
tion for PCV-10 and PCV-13.
Figure 3 shows the impact of varying the level of net
indirect effects of vaccination in individuals aged
5 years or over. At least 14% of the estimated net indir-
ect effect would be needed in order to make PCV-7
cost effective (that is, less than €50 000 per QALY).
Several scenario analyses are displayed in table 4,
which again show the large impact of indirect effects
and reduced dose schedules on the cost effectiveness
of pneumococcal vaccination.
Finally, figure 4 shows cost effectiveness acceptabil-
ity curves for six different scenarios. This figure clearly
shows that administering PCV-7 in a 3+1 dose sche-
dule cannot be considered as cost effective compared
with no vaccination. The incremental cost effective-
ness ratios of PCV-10 and PCV-13 are likely to be
more favourable than that for PCV-7, yet still the
total costs of vaccination should be reduced in order
to unambiguously consider vaccination cost effective.
DISCUSSION
Our economic analysis indicates that the current
national vaccination programme with PCV-7 in the
Netherlands is not cost effective.As several papers sug-
gest that lowering the number of doses from four to
three will not affect the vaccine efficacy for the pneu-
mococcal vaccine,11 28 29 31 we investigated the potential
impact of such reduced-dose schedules. Although a 2
+1 reduced dose schedule could lower the total cost of
vaccination and, therefore, reduce the incremental cost
effectiveness ratio by approximately 30%, it is unlikely
that universal vaccination with PCV-7 will become
acceptable on the grounds of cost effectiveness.
More favourable incremental cost effectiveness
ratios were shown for PCV-10 and PCV-13, as long
as net positive indirect effects for individuals aged
5 years or older were included in the analyses. In par-
ticular, scenarios that used reduced total vaccination
costs by using a 2+1 dose schedule showed that incre-
mental cost effectiveness ratios would decrease down
to €37 891 and €35 743 per QALY for PCV-10 and
PCV-13, respectively. These ratios are likely to be con-
sidered as cost effective given various country specific
thresholds.
Strengths and weaknesses
This is the first economic evaluation of national vacci-
nation against pneumococcal disease that has included
serotype replacement for the analysed birth cohort by
using post-vaccination data.12 13 We estimated the
number of cases of invasive pneumococcal disease
averted by vaccination and the increase in invasive
pneumococcal disease caused by non-vaccine sero-
types on the basis of the most recent data available.17
Given the relatively small number of cases reported
during the surveillance period of two years, our predic-
tions regarding the increase of disease caused by non-
vaccine serotypes may have limited precision; how-
ever, they are based on the best data currently avail-
able. In particular, the estimated increase of 100% for
invasive disease caused by serotypes not covered by
PCV-7 was based on national observational studies
from the Netherlands and the UK.12 13 17 On the one
hand, this specific assumption may be too pessimistic.
On the other hand, data from theUK show an ongoing
increase in the cases of invasive pneumococcal disease
caused by non-vaccine serotypes and no plateau has
yet been reached in the third year after PCV-7 intro-
duction, suggesting that the eventual increase in dis-
ease caused by non-vaccine serotypes might even be
higher.12 There are, however, some important differ-
ences between theNetherlands and theUK. In contrast
to the Netherlands, the UK uses a reduced dose sche-
dule of PCV-7 at 2, 4, and 13 months. Also, the intro-
































































































































































































Fig 2 | Sensitivity analysis on the base case cost effectiveness ratio for the seven valent
pneumococcal conjugated vaccine. The parameters were varied by 25%. Dark bars show the
incremental cost effectiveness ratio after a 25% decrease in the parameter, whereas light bars
show the incremental cost effectiveness ratio after a 25% increase (note that it was not
possible to increase vaccine efficacy). QALY, quality adjusted life year
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programme for all children aged less than 2 years. In
the Netherlands, by contrast, vaccination was imple-
mented without a catch-up programme. Several alter-
native scenarios regarding serotype replacement were
explored in the sensitivity analyses, which showed that
our conclusions regarding the incremental cost effec-
tiveness ratios for all three vaccines were quite robust.
In our base case analysis for PCV-7,we assumed that
there was no net indirect effect of vaccination for indi-
viduals outside the modelled birth cohort because no
overall reduction in invasive pneumococcal disease in
non-vaccinees has been observed in any European
country, in contrast to the US.12 13 15 The difference
between results obtained in theUS and those recorded
in Europe may be partly explained by the 60% to 70%
coverage of the seven vaccine serotypes in Europe,
compared with the more than 80% coverage in the
US.32 This disparity leavesmore room for replacement
disease in Europe. Country specific differences in the
circulating serotypes causing disease (inclusive of secu-
lar changes in time) could also contribute to the lower
overall reduction of invasive pneumococcal disease in
Europe compared with the US.33 Furthermore, in the
Netherlands, as in most parts of Europe, the baseline
incidence rates of invasive pneumococcal disease in
children are substantially lower than in the US and
almost exclusively based on culture confirmed cases
of children admitted to hospital.17 34 Another poten-
tially relevant difference in the introduction of PCV-7
in the Netherlands compared with the US is the high
vaccine uptake (>95%) among all newborns in the
Netherlands for all four doses of the vaccination,
which could potentially lead to more rapid develop-
ment of replacement disease.34
Potential net indirect effects in non-vaccinees were
modelled using straightforward calculus. Ideally, the
impact of pneumococcal vaccination should have
been modelled using a so called dynamic transmission
model, in which the transmission and carriage of Strep-
tococcus pneumoniae is taken explicitly into account.
However, because the transition dynamics of S pneu-
moniae are complex and serotype dependent, and
detailed data regarding these transmission dynamics
are also quite limited, dynamically modelling all rele-
vant serotypes of S pneumoniae would be very compli-
cated. For PCV-10 and PCV-13, a net indirect effect of
10% was included in the base case analysis. This esti-
mate of indirect benefit may be conservative if com-
pared with the much higher net indirect protective
benefits observed in the US after implementation of
routine vaccination with similar or lower vaccine ser-
otype coverage.2-4
Furthermore, we did not include the benefits arising
from the prevention of antibiotic resistance in our
model because the impact of this inclusion is expected
to be small given that penicillin resistance is less than
0.4% in the Netherlands.17 Finally, similar to almost all
previous cost effectiveness analyses for pneumococcal
vaccination, our analytic time frame was equal to the
assumed protection period, after which we assumed
that health effects and costs would be similar in the
vaccinated and unvaccinated group.
Comparison with other studies
The cost effectiveness of PCV-7 is worse than that cal-
culated in our previous studies and in other recent
health economic studies.5-10 16 18 35 This disparity is
mostly because of the exclusion of herd protection
effects and the inclusion of serotype replacement in
our study. Other factors contributing to the worse
incremental cost effectiveness ratio were the use of a
lower death rate for invasive pneumococcal disease
and lower indirect costs than in our previous
studies.6 16
Several recently published cost effectiveness studies
included net vaccine benefits for unvaccinated adults
and elderly people in their base case analysis.5-7 9 35
These studies reported vaccination to be cost saving59
or at least cost effective.6 7 35 The three studies that
excluded herd protection in the base case analysis
reported relatively unfavourable cost effectiveness
ratios for PCV-7 compared with other recommended
infant vaccinations.8 16 18 When we excluded the
increase in invasive pneumococcal disease caused by
non-vaccine serotypes but left all other assumptions
the same as in the base case analysis, our results were
similar to those of these three studies—that is, we found
an unfavourable cost effectiveness ratio.8 16 18
Our cost effectiveness results show that the current
vaccination schedule for PCV-7 might be far more
expensiveperQALYgained comparedwith other rou-
tine infant vaccination programmes recently imple-
mented, such as for human papilloma virus36, or with
other vaccines that have not yet been implemented in a
national programme in the Netherlands, such as hepa-
titis B37 and varicella.38
Implications and future research
Administration of PCV-7 at 2, 3, 4, and 11months was
introduced to the Netherlands as part of the national
immunisation programme in 2006 partially on the
basis of favourable cost effectiveness data. The current
analysis shows unfavourable cost effectiveness of the



























Fig 3 | The effect on cost effectiveness ratios of varying the
level of net indirect effect of vaccination for individuals aged
5 years or older. The horizontal dashed line shows the
threshold at €50000 per QALY. PCV-7/10/13, seven/10/13
valent pneumococcal conjugated vaccine ( 3+1 dose
schedule); QALY, quality adjusted life year
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PCV-7 3+1 dose schedule because of increases in inva-
sive disease caused by non-vaccine serotypes, which
offset the herd protective benefits in individuals out-
side the analysed birth cohort. Although the cost effec-
tiveness of PCV-7 is unfavourable from a health
economics point of view, it is favourable from a public
health point of view—a significant decrease in cases of
pneumococcal disease has occurred in theNetherlands
over the past two years.13 Switching to the 10 valent or
13 valent vaccine would extend the serotype coverage
to a higher level than that currently achieved with
PCV-7, which might reduce the potential for disease
caused by non-vaccine serotypes and increase the
overall benefits in vaccinated children.
Herd protective effects are more likely to occur with
broad vaccine coverage, rendering vaccination poten-
tially cost effective. Vaccination would be particularly
cost effective if a more valent vaccine is used in combi-
nation with dose reductions, price reductions, or both.
Our paper should help guide future decisions to
potentially reduce doses of pneumococcal vaccine or
to shift from PCV-7 to vaccines that cover additional
serotypes. Further research should be directed to
building a dynamic model to entangle and explicitly
predict the indirect effects of disease replacement and
herd protection on vaccine efficacy and thus further
enhance the validity of cost effectiveness approaches
applied to pneumococcal vaccination.
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